79 The unfolded protein response is initiated by three ER transmembrane
sensors, PKR-like ER kinase, inositol-requiring enzyme 1, and activating transcription factor 6. These transmembrane sensors activate an adaptive response that results in cessation of protein synthesis, increase of protein-folding chaperones, and increase in ER-associated degradation LY294002 genes. The unfolded protein response is also able to induce activation of the c-Jun N-terminal kinase pathway and thereby inhibit insulin signaling through the subsequent phosphorylation and/or degradation of IRS1.80 Recent data from experimental models indicate that ER stress is critical to the initiation and integration of pathways of inflammation and insulin action in obesity, T2DM, and NAFLD. ER stress response can be induced in the liver by saturated FA in rats,81 and this activation can lead to activation of c-Jun N-terminal kinase and insulin resistance.80 Activation of ER stress in the liver has also been shown in human subjects with NAFLD, as documented by activation of PKR-like ER kinase
and an increase in the ER chaperone GRP78 messenger RNA.82 Talazoparib clinical trial Data from a study conducted in extremely obese patients revealed that ER stress is associated with NAFLD and improves with weight loss and resolution of steatosis. Bariatric surgery–induced weight loss increased insulin sensitivity in multiple organs and decreased IHTG content and both liver and adipose tissue activation of all three ER stress click here pathways.83 The complexity of the relationship between NAFLD and insulin resistance is underscored by the observation that steatosis is not always associated with insulin resistance. A dissociation between
steatosis and insulin resistance has been reported in selected genetically altered or pharmacologically manipulated animal models and human subjects. Overexpression of hepatic DGAT,69 blockade of hepatic VLDL secretion,66 and pharmacological blockade of β-oxidation84 in mice causes hepatic steatosis, but not hepatic or skeletal muscle insulin resistance, whereas inhibiting hepatocyte TG synthesis in obese mice decreases hepatic steatosis but does not improve insulin sensitivity.85 In addition, hepatic steatosis caused by genetic deficiency of apoB synthesis and decreased VLDL hepatic secretion in patients with familial hypobetalipoproteinemia is not accompanied by hepatic or peripheral insulin resistance (S. Klein, unpublished observations). These data support the notion that hepatic accumulation of TG does not necessarily cause insulin resistance. In fact, it is possible that the esterification of excessive FA to inert TG molecules protects the hepatocyte by preventing the accumulation of potentially toxic intracellular FAs.86 Inhibiting hepatocyte TG synthesis by treatment with DGAT2 antisense oligonucleotide in obese mice decreased hepatic steatosis but increased hepatic FFAs, markers of lipid peroxidation/oxidant stress, lobular necroinflammation, and fibrosis.